secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001599298-24-000064
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics appoints Dr. Mostafa Ronaghi to board of directors
----------------------------------------------------------------------

- Dr. Ronaghi elected to board and Compensation Committee effective April 11, 2024.
- Received option grant per non-employee director compensation policy; indemnification agreement.
- Former CTO and SVP at Illumina (2008-2021); co-founded GRAIL in 2016.
- Summit CEO cites Ronaghi's expertise in genomics to help maximize ivonescimab potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000064/0001599298-24-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000064/smmt-20240411.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer